-- 上海ヘンリウスバイオテック（香港証券取引所：2696）は、注射剤HLX43の第2/3相臨床試験について、日本の医薬品医療機器総合機構（PMDA）から承認を得たと、月曜日に香港証券取引所に提出した書類で明らかにした。 この薬剤は、進行性扁平上皮非小細胞肺がんを対象に、単剤療法またはピムルタマブHLX07との併用療法として、ドセタキセルと比較試験される。 同社は、関連条件が満たされ次第、試験を開始する予定である、と書類には記載されている。
Related Articles
Mining & Metals
Panoro Minerals Announcing Brokered LIFE Offering for Gross Proceeds of up to $20M
$PML.V
Research
Raymond James Upgrades Acadia Healthcare to Strong Buy From Outperform, Adjusts Price Target to $39 From $25
Acadia Healthcare Company (ACHC) has an average rating of overweight and mean price target of $28.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ACHC
Research
Cantor Fitzgerald Upgrades GlobalFoundries to Overweight From Neutral, Adjusts Price Target to $80 From $50
GlobalFoundries (GFS) has an average rating of overweight and mean price target of $54.68, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GFS